A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c + GR-1 + dendritic cell subset that promotes the Th17 response

Immunity Inflammation and Disease

Volumn 3, Issue 4, 2015, Pages 360-373

  Liang, Dongchun ^a   Zuo, Aijun ^a   Shao, Hui ^b   Chen, Mingjiazi ^a   Kaplan, Henry J ^b   Sun, Deming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Adenosine receptors; Autoimmunity; Experimental autoimmune uveitis; IL 17; Th17; Uveitis; T cells

Indexed keywords

EID: 84975906632     PISSN: None     EISSN: 20504527     Source Type: Journal    
DOI: 10.1002/iid3.74     Document Type: Article

References (58)

1. Fredholm, B. B., A. P. IJzerman, K. A. Jacobson, J. Linden, and C. E. Müller. 2011. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. Pharmacol. Rev. 63:1–34.
2. Cronstein, B. N., R. I. Levin, J. Belanoff, G. Weissmann, and R. Hirschhorn. 1986. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:760–770.
3. Stagg, J., U. Divisekera, H. Duret, T. Sparwasser, M. W. L. Teng, P. K. Darcy, and M. J. Smyth. 2011. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71:2892–2900.
4. Jin, D., J. Fan, L. Wang, L. F. Thompson, A. Liu, B. J. Daniel, T. Shin, et al. 2010. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70:2245–2255.
5. Beavis, P. A., J. Stagg, P. K. Darcy, and M. J. Smyth. 2012. CD73: a potent suppressor of antitumor immune responses. Trend. Immunol. 33:231–237.
6. Wang, L., J. Fan, L. F. Thompson, Y. Zhang, T. Shin, T. J. Curiel, and B. Zhang. 2011. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121:2371–2382.
7. Hoskin, D. W, J. S. Mader, S. J. Furlong, D. M. Conrad, and J. Blay. 2008. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Int. J. Oncol. 32:527–535.
8. Wilson, J. M., C. Kurtz, S. G. Black, W. G. Ross, M. S. Alam, J. Linden, and P. B. Ernst. 2011. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. J. Immunol. 186:6746–6752.
9. Zaynagetdinov, R., S. Ryzhov, A. E. Goldstein, H. Yin, S. V. Novitskiy, K. Goleniewska, V. V. Polosukhin, et al. 2010. Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. Am. J. Resp. Cell Mol. Biol. 2010/05/01;Sect. 564–571.
10. Zarek, P. E., C-T. Huang, E. R. Lutz, J. Kowalski, M. R. Horton, J. Linden, C. G. Drake, et al. 2008. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111:251–259.
11. Hasko, G., and B. N. Cronstein. 2004. Adenosine: an endogenous regulator of innate immunity. Trend. Immunol. 25:33–39.
12. Sitkovsky, M. V., D. Lukashev, S. Apasov, H. Kojima, M. Koshiba, C. Caldwell, A. Ohta, et al. 2004. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Ann. Rev. Immunol. 22:657–682.
13. Sitkovsky, M. V., and A. Ohta. 2005. The ’danger’ sensors that STOP the immune response: the A2 adenosine receptors? Trend. Immunol. 26:299–304.
14. Hasko, G., J. Linden, B. Cronstein, and P. Pacher. 2008. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7:759–770.
15. Novitskiy, S. V., S. Ryzhov, R. Zaynagetdinov, A. E. Goldstein, Y. Huang, O. Y. Tikhomirov, M. R. Blackburn, et al. 2008. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112:1822–1831.
16. Naganuma, M., E. B. Wiznerowicz, C. M. Lappas, J. Linden, M. T. Worthington, and P. B. Ernst. 2006. Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177:2765–2769.
17. Ohta, A., and M. Sitkovsky. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916–920.
18. Vincenzi, F., M. Padovan, M. Targa, C. Corciulo, S. Giacuzzo, S. Merighi, S. Gessi, et al. 2013. A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLoS ONE 8:e54195.
19. Kolachala, V. L., B. K. Ruble, M. Vijay-Kumar, L. Wang, S. Mwangi, H. E. Figler, R. A. Figler, et al. 2008. Blockade of adenosine A2B receptors ameliorates murine colitis. Brit. J. Pharmacol. 155:127–137.
20. Belikoff, B. G., L. J. Vaickus, M. Sitkovsky, and D. G. Remick. 2012. A2B adenosine receptor expression by myeloid cells is proinflammatory in murine allergic-airway inflammation. J. Immunol. 189:3707–3713.
21. Fredholm, B. B., I. J. AP, K. A. Jacobson, K. N. Klotz, and J. Linden. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:527–552.
22. Blackburn, M., C. Vance, E. Morschl, and C. Wilson. 2009. Adenosine receptors and inflammation. Pp. 215–69 in C. N. Wilson, and S. J. Mustafa, eds. Adenosine receptors in health and disease. Springer, Berlin Heidelberg.
23. Alam, M. S., C. C. Kurtz, J. M. Wilson, B. R. Burnette, E. B. Wiznerowicz, W. G. Ross, J. M. Rieger, et al. 2009. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol. 2:232–242.
24. Odashima, M., G. Bamias, J. Rivera-Nieves, J. Linden, C. C. Nast, C. A. Moskaluk, M. Marini, et al. 2005. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology 129:26–33.
25. Hasko, G., B. Csoka, Z. H. Nemeth, E. S. Vizi, and P. Pacher. 2009. A2B adenosine receptors in immunity and inflammation. Trends Immunol. 30:263–270.
26. Ryzhov, S., R. Zaynagetdinov, A. E. Goldstein, S. V. Novitskiy, M. M. Dikov, M. R. Blackburn, I. Biaggioni, et al. 2008. Effect of A2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. J. Immunol. 180:7212– 7220.
27. Liang, D., A. Zuo, H. Shao, M. Chen, H. J. Kaplan, and D. Sun. 2014. Roles of the adenosine receptor and CD73 in the regulatory effect of gd T cells. PLoS ONE 9:e108932.
28. + uveitogenic T cells. J. Immunol. 183: 560–567.
29. + uveitogenic T cells. Invest. Ophthalmol. Vis. Sci. 51:4661–4667.
30. Nian, H., H. Shao, B. A. O’Brien, W. K. Born, and H. J. K. Sun. 2011. Activated gd cells promote the activation of uveitogenic T cells and exacerbate EAU development. Invest. Ophthalmol. Vis. Sci. 52:5920–5927.
31. Nian, H., D. Liang, A. Zuo, R. Wei, H. Shao, W. K. Born, H. J. Kaplan, et al. 2012. Characterization of autoreactive and bystander IL-17+ T cells induced in immunized C57BL/6 mice. Invest. Ophthalmol. Vis. Sci. 53:879–905.
32. Liang, D., A. Zuo, H. Shao, W. K. Born, R. L. O’Brien, H. J. Kaplan, and D. Sun. 2013. IL-23 receptor expression on gd T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis. J. Immunol. 191:1118–1125.
33. Liang, D., A. Zuo, H. Shao, M. Chen, H. J. Kaplan, and D. Sun. 2014. Anti-or pro-inflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environmental-dependent. J. Immunol. 193: 5498–5505.
34. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, et al. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693–1702.
35. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131–137.
36. + dendritic cells in the generation of Th17 autoreactive T cells in autoimmune experimental uveitis. J. Immunol. 188:5785–5791.
37. Liang, D., A. Zuo, H. Shao, W. K. Born, R. L. O’Brien, H. J. Kaplan, and D. Sun. 2013. Retinoic acid inhibits CD25+ dendritic cell expansion and gd T-cell activation in experimental autoimmune uveitis. Invest. Ophthal. Vis. Sci. 54:3493–3503.
38. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238.
39. Dong, C. 2006. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6:329–334.
40. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:560–567.
41. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity. 21:467–476.
42. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, et al. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201:233–240.
43. Sitkovsky, M. V. 2009. T regulatory cells: hypoxia-adenosi-nergic suppression and re-direction of the immune response. Trends Immunol. 30:102–108.
44. Mandler, R., R. E. Birch, S. H. Polmar, G. M. Kammer, and S. A. Rudolph. 1982. Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 79:7542–7546.
45. Mills, J. H., L. F. Thompson, C. Mueller, A. T. Waickman, S. Jalkanen, J. Niemela, L. Airas, et al. 2008. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 105:9325–9330.
46. Niemela, J., I. Ifergan, G. G. Yegutkin, S. Jalkanen, A. Prat, and L. Airas. 2008. IFN-b regulates CD73 and adenosine expression at the blood-brain barrier. Eur. J. Immunol. 38:2718–2726.
47. Ramlackhansingh, A. F., S. K. Bose, I. Ahmed, F. E. Turkheimer, N. Pavese, and D. J. Brooks. 2011. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76:1811–1816.
48. Sevigny, C. P., L. Li, A. S. Awad, L. Huang, M. McDuffie, J. Linden, P. I. Lobo, et al. 2007. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J. Immunol. 178:4240–4249.
49. Wei, W., C. Du, J. Lv, G. Zhao, Z. Li, Z. Wu, G. Hasko, et al. 2013. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J. Immunol. 190:138–146.
50. Kusu, T., H. Kayama, M. Kinoshita, S. G. Jeon, Y. Ueda, Y. Goto, R. Okumura, et al. 2013. Ecto-nucleoside triphosphate diphosphohydrolase 7 controls Th17 cell responses through regulation of luminal ATP in the small intestine. J. Immunol. 190:774–783.
51. Doherty, G. A., A. Bai, D. Hanidziar, M. S. Longhi, G. O. Lawlor, P. Putheti, E. Csizmadia, et al. 2012. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur. J. Immunol. 42:3062– 3072.
52. Panther, E. L. I. S., M. A. R. C. Idzko, Y. A. R. E. Herouy, H. E. N. R. Rheinen, P. J. Gebrick-Haerter, U. L. R. I. Mrowietz, S. T. E. F. Dichmann, et al. 2001. Expression and function of adenosine receptors in human dendritic cells. FASEB. J. 15:1963–1970.
53. Najar, H. M., S. Ruhl, A. C. Bru-Capdeville, and J. H. Peters. 1990. Adenosine and its derivatives control human monocyte differentiation into highly accessory cells versus macrophages. J. Leuk. Biol. 47:429–439.
54. Fredholm, B. B., E. Irenius, B. Kull, and G. Schulte. 2001. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 61: 443–448.
55. Raveney, B. J. E., D. A. Copland, A. D. Dick, and L. B. Nicholson. 2009. TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis. J. Immunol. 183.
56. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162–174.
57. Zhu, B., Y. Bando, S. Xiao, K. Yang, A. C. Anderson, V. K. Kuchroo, and S. J. Khoury. 2007. CD11b+Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179:5228–5237.
58. Marhaba, R., M. Vitacolonna, D. Hildebrand, M. Baniyash, P. Freyschmidt-Paul, and M. Zoller. 2007. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J. Immunol. 179:5071–5081.